Phase
Condition
Ankylosing Spondylitis
Treatment
Tofacitinib 5 MG
Clinical Study ID
Ages 18-45 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Clinical diagnosis of axSpA and fulfilment of the ASAS classification criteria
Symptom (back pain) duration for ≤ 2 years, according to the definition of earlyaxial SpA by ASAS.
Active disease activity as defined by: BASDAI ≥4 and back pain score (BASDAIquestion 2) of ≥4 AND objective signs of inflammation evident by osteitis in MRI ofSIJ AND/OR elevated serum CRP levels.
Exclusion
Exclusion criteria:
active current infection, severe infections in the last 3 months
history of recurrent Herpes zoster or disseminated Herpes simplex
immunodeficiency
chronic Hepatitis B, C or HIV infection
women: pregnant or lactating (have to practice reliable method of contraception)
other severe diseases conflicting with a clinical study, contraindications for MRI
Study Design
Connect with a study center
Charité Universitätsmedizin Berlin
Berlin,
GermanyActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.